Posted by Michael Wonder on 04 Mar 2025
Roche Korea’s multiple sclerosis drug scores reimbursement
4 March 2025 - Roche Korea said its multiple sclerosis treatment, Ocrevus (ocrelizumab), started receiving reimbursement from last Saturday.
With this reimbursement approval, Ocrevus is now covered as a monotherapy for patients with relapsing forms of multiple sclerosis, including relapsing-remitting multiple sclerosis patients who failed or showed insufficient response to first-line treatments such as interferon β-1b and are eligible for outpatient treatment, as well as secondary progressive multiple sclerosis patients, where Ocrevus is recognised as a first-line treatment.
